Andrzej Duda's statement at Celon Pharma S.A.

Poland Andrzej Duda · President of Poland

24 February 2021 · Celon Pharma S.A. laboratories

Context
Duda visited Celon Pharma's laboratories near Warsaw on February 24, 2021, to highlight Polish pharmaceutical innovation and COVID-19 drug research efforts.
Main themes
COVID-19 drug research, Polish pharmaceutical innovation, Celon Pharma, biotechnology and R&D, oncological and neuropsychiatric drugs, clinical trials, Polish scientific achievement, company growth and development
Duration
~5 min
16th percentile
Words
592
16th percentile
Sentences
28
16th percentile
Readability
43
43rd percentile
Grade
11.9
43rd percentile
Syntax
3.20
73rd percentile
Vocabulary
2.08
23rd percentile

Translated from Polish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 36%36%
  • Technological 32%32%
  • Social 18%18%
  • Ceremonial 14%14%
  • Geopolitical 0%0%
  • Environmental 0%0%
  • Institutional 0%0%
  • Not in focus 0%

28 sentences in 12 paragraphs

Good morning, Ladies and Gentlemen!

We are in an extraordinary place in our country – we are at the laboratories of Celon Pharma, which is engaged in biotechnology and pharmaceutical research, as well as drug production. In this regard, it is undoubtedly one of the most modern companies in Poland – it is at the forefront of innovation in this field.

With me is Dr. Maciej Wieczorek, the president of Celon Pharma, as well as the owner of the majority of shares in this company, as it is a publicly traded company, and above all – most importantly – it is a Polish company.

Mr. President founded Celon Pharma in 2002, so it can be confidently said – looking at this extremely impressive development – that it is a very young company. At the same time, it already has a very serious achievement in the pharmaceutical world, in the world of drugs – not only in their production but, most importantly, in drug research.

The Research and Development Center was established in 2006, marking its beginnings. Since then, research has been ongoing. Today, 160 scientists work here, many of whom already hold a doctorate – they are chemists, biologists, molecular biologists, biotechnologists who conduct drug research here, in the laboratories of Celon Pharma, every day.

Currently, there are 15 innovative drug projects being conducted here, meaning work is continuously ongoing on 15 different drug preparations, five of which are already at the clinical trial stage. Most importantly – research is being conducted here on oncological drugs, neuropsychiatric drugs, as well as drugs against the coronavirus.

Looking at the situation in our country, in Europe, and in the world today, this element of research for us – ordinary people; those who are waiting for the preparations that will protect us, cure us from the coronavirus – is the most important.

A moment ago, I had the great pleasure of seeing both the facility and the laboratories. Mr. President showed me the various laboratories where research is ongoing; I spoke with the scientists who conduct it on a daily basis.

Indeed, this is a great hope not only for us, not only for Poland – but it can be confidently said that it is also for Europe and the world. Because these drugs against COVID will have several variants, which Mr. President will certainly discuss shortly. But above all, the Polish company is conducting research from scratch here – this is entirely our achievement, Polish thought, Polish hands.

And above all, this is indeed a tremendous hope for the future, for the development of Polish pharmacy. Because the equipment that you see here is absolutely world-class. These are devices that allow research to be conducted in the best-equipped laboratories in the world. And such laboratories are available here – in our country, just outside Warsaw – at Celon Pharma.

I am extremely pleased that the company is growing and developing. Mr. President plans that in the relatively near future, not 160, but even 350 scientists will be working at the company. Today, the entire company consists of 500 employees. The company's development is ongoing. You can see these beautiful facilities with further development plans.

So I wholeheartedly congratulate you, Mr. President, and I keep my fingers crossed for the research to succeed, so that we – as you announced, Mr. President – can see a preparation against the coronavirus on the market in 2022. Meanwhile, that you can proceed to clinical trials – as planned – already in the third quarter of this year.